TR200201094T2 - Farmasötik maddeler olarak bisiklik amino asitler - Google Patents

Farmasötik maddeler olarak bisiklik amino asitler

Info

Publication number
TR200201094T2
TR200201094T2 TR2002/01094T TR200201094T TR200201094T2 TR 200201094 T2 TR200201094 T2 TR 200201094T2 TR 2002/01094 T TR2002/01094 T TR 2002/01094T TR 200201094 T TR200201094 T TR 200201094T TR 200201094 T2 TR200201094 T2 TR 200201094T2
Authority
TR
Turkey
Prior art keywords
amino acids
disorders
pharmaceuticals
bicyclic amino
compounds
Prior art date
Application number
TR2002/01094T
Other languages
English (en)
Turkish (tr)
Inventor
Stephen Bryans Justin
Clive Blakemore David
Osborne Simon
Receveur Jean-Marie
Original Assignee
Warner-Lambert Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner-Lambert Company filed Critical Warner-Lambert Company
Publication of TR200201094T2 publication Critical patent/TR200201094T2/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/28—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and containing rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/14—All rings being cycloaliphatic
    • C07C2602/18—All rings being cycloaliphatic the ring system containing six carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/14—All rings being cycloaliphatic
    • C07C2602/20—All rings being cycloaliphatic the ring system containing seven carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/14—All rings being cycloaliphatic
    • C07C2602/22—All rings being cycloaliphatic the ring system containing eight carbon atoms, e.g. pentalene
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/14—All rings being cycloaliphatic
    • C07C2602/24—All rings being cycloaliphatic the ring system containing nine carbon atoms, e.g. perhydroindane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/14—All rings being cycloaliphatic
    • C07C2602/26—All rings being cycloaliphatic the ring system containing ten carbon atoms
    • C07C2602/28—Hydrogenated naphthalenes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Anesthesiology (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
TR2002/01094T 1999-10-20 2000-10-17 Farmasötik maddeler olarak bisiklik amino asitler TR200201094T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US16072599P 1999-10-20 1999-10-20

Publications (1)

Publication Number Publication Date
TR200201094T2 true TR200201094T2 (tr) 2002-09-23

Family

ID=22578159

Family Applications (2)

Application Number Title Priority Date Filing Date
TR2002/01094T TR200201094T2 (tr) 1999-10-20 2000-10-17 Farmasötik maddeler olarak bisiklik amino asitler
TR2005/00221T TR200500221T2 (tr) 1999-10-20 2000-10-17 Farmasötik Maddeler Olarak Bisiklik Amino Asitler

Family Applications After (1)

Application Number Title Priority Date Filing Date
TR2005/00221T TR200500221T2 (tr) 1999-10-20 2000-10-17 Farmasötik Maddeler Olarak Bisiklik Amino Asitler

Country Status (50)

Country Link
US (2) US6689906B1 (enExample)
EP (2) EP1226110B1 (enExample)
JP (2) JP3632191B2 (enExample)
KR (2) KR100593349B1 (enExample)
CN (1) CN1165518C (enExample)
AP (2) AP2004003186A0 (enExample)
AR (2) AR026087A1 (enExample)
AT (2) ATE358116T1 (enExample)
AU (2) AU778871B2 (enExample)
BG (2) BG106719A (enExample)
BR (1) BR0014972B1 (enExample)
CA (1) CA2386297C (enExample)
CO (1) CO5280060A1 (enExample)
CR (1) CR6620A (enExample)
CU (1) CU23112A3 (enExample)
CZ (1) CZ295960B6 (enExample)
DE (2) DE60019628T2 (enExample)
DO (1) DOP2000000083A (enExample)
DZ (1) DZ3197A1 (enExample)
EA (1) EA005206B1 (enExample)
EC (1) ECSP045393A (enExample)
EE (1) EE200200211A (enExample)
ES (2) ES2282785T3 (enExample)
GE (1) GEP20043297B (enExample)
GT (2) GT200000183A (enExample)
HK (1) HK1049826B (enExample)
HN (1) HN2000000224A (enExample)
HR (2) HRP20040709A2 (enExample)
HU (1) HUP0203325A3 (enExample)
IL (3) IL149143A0 (enExample)
IS (2) IS6348A (enExample)
MA (1) MA26842A1 (enExample)
MX (1) MXPA02003229A (enExample)
MY (1) MY127678A (enExample)
NO (2) NO20021780L (enExample)
NZ (1) NZ517961A (enExample)
OA (1) OA12070A (enExample)
PA (1) PA8505201A1 (enExample)
PE (1) PE20010740A1 (enExample)
PL (1) PL354607A1 (enExample)
PT (1) PT1226110E (enExample)
SI (1) SI1226110T1 (enExample)
SK (1) SK5232002A3 (enExample)
SV (1) SV2001000188A (enExample)
TR (2) TR200201094T2 (enExample)
TW (2) TW200505824A (enExample)
UA (1) UA72931C2 (enExample)
WO (1) WO2001028978A1 (enExample)
YU (2) YU29302A (enExample)
ZA (1) ZA200202543B (enExample)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7164034B2 (en) 1999-06-10 2007-01-16 Pfizer Inc. Alpha2delta ligands for fibromyalgia and other disorders
NZ522480A (en) * 2000-06-26 2005-06-24 Warner Lambert Co Gabapentin analogues for sleep disorders
US6620829B2 (en) 2000-10-17 2003-09-16 Warner-Lambert Company Method of treating noninflammatory cartilage damage
EP1226820A1 (en) 2001-01-26 2002-07-31 Warner-Lambert Company Use of bicyclic amino acids for preventing and treating visceral pain and gastrointestinal disorders
CA2444053C (en) * 2001-04-19 2008-06-17 Warner-Lambert Company Llc Fused bicyclic or tricyclic amino acids
GB2375109A (en) * 2001-05-04 2002-11-06 Warner Lambert Co Process for preparing bicyclic amino acid
GB2375108A (en) * 2001-05-04 2002-11-06 Warner Lambert Co Production of a bicycloheptanone
US6818787B2 (en) 2001-06-11 2004-11-16 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US7232924B2 (en) 2001-06-11 2007-06-19 Xenoport, Inc. Methods for synthesis of acyloxyalkyl derivatives of GABA analogs
AU2002310409C1 (en) * 2001-06-11 2008-04-17 Xenoport, Inc. Orally administered dosage forms of GABA analog prodrugs having reduced toxicity
US8048917B2 (en) 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US7186855B2 (en) 2001-06-11 2007-03-06 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
PL371944A1 (en) 2002-01-31 2005-07-11 Warner-Lambert Company Llc Alpha 2 delta ligands to treat tinnitus
RU2286151C2 (ru) * 2002-02-22 2006-10-27 Уорнер-Ламберт Компани Ллс Комбинации альфа-2-дельта-лиганда с селективным ингибитором циклооксигеназы-2
JP2005534678A (ja) * 2002-06-27 2005-11-17 ワーナー−ランバート カンパニー リミティド ライアビリティー カンパニー 注意欠陥多動性障害の治療方法
US7419981B2 (en) 2002-08-15 2008-09-02 Pfizer Inc. Synergistic combinations of an alpha-2-delta ligand and a cGMP phosphodieterse 5 inhibitor
GB0219024D0 (en) * 2002-08-15 2002-09-25 Pfizer Ltd Synergistic combinations
BR0313432A (pt) * 2002-08-15 2005-07-12 Pfizer Uso terapêutico de aminoácidos bicìclicos ou tricìclicos fundidos
GB0223072D0 (en) 2002-10-04 2002-11-13 Pfizer Ltd Cyclic nitromethyl acetic acid derivatives
US7018818B2 (en) 2002-10-04 2006-03-28 Pfizer Inc. Intermediates in the preparation of therapeutic fused bicyclic amino acids
AU2003297927A1 (en) 2002-12-11 2004-06-30 Xenoport, Inc. Prodrugs of fused gaba analogs, pharmaceutical compositions and uses thereof
PT1572173E (pt) 2002-12-13 2010-05-10 Warner Lambert Co Ligando alfa-2-delta para tratar sintomas do tracto urinário inferior
CA2451267A1 (en) 2002-12-13 2004-06-13 Warner-Lambert Company Llc Pharmaceutical uses for alpha2delta ligands
EP2172197A1 (en) 2002-12-13 2010-04-07 Warner-Lambert Company LLC Octanoic acid derivative to treat fibromyalgia and other pains
ATE449633T1 (de) 2003-09-12 2009-12-15 Pfizer Kombinationen aus alpha-2-delta liganden und serotonin / noradrenalin-wiederaufnahmehemmern
WO2006092692A1 (en) * 2005-03-01 2006-09-08 Pfizer Limited Use of combinations of pde7 inhibitors and alpha-2-delty ligands for the treatment of neuropathic pain
AR061728A1 (es) * 2006-06-30 2008-09-17 Pfizer Prod Inc Composicion para tratamiento usando compuestos selectivos alfa-2-delta-1
CN102058885B (zh) 2006-12-22 2013-04-10 瑞蔻达蒂爱尔兰有限公司 采用α2δ配体和NSAID的下泌尿道疾病的联合治疗
KR101335784B1 (ko) 2007-09-28 2013-12-05 다이이찌 산쿄 가부시키가이샤 2 고리성 γ-아미노산 유도체
WO2010110361A1 (ja) * 2009-03-26 2010-09-30 第一三共株式会社 二環性γ-アミノ酸誘導体の製造方法
BR112013031360B1 (pt) 2011-06-08 2022-01-25 Daiichi Sankyo Company, Limited Método para produzir um composto
ES2649968T3 (es) 2011-06-08 2018-01-16 Daiichi Sankyo Company, Limited Procedimiento de producción de un compuesto bicíclico vía transposición de Claisen
HUE040225T2 (hu) 2011-12-15 2019-02-28 Daiichi Sankyo Co Ltd Eljárás biciklikus vegyület optikai elválasztására aszimmetrikus katalizátort felhasználva
HUE033397T2 (en) 2012-04-10 2017-12-28 Daiichi Sankyo Co Ltd A method for the optical separation of bicyclic compounds by an enzyme
US9066853B2 (en) 2013-01-15 2015-06-30 Warsaw Orthopedic, Inc. Clonidine compounds in a biodegradable fiber
TWI635071B (zh) 2013-07-08 2018-09-11 第一三共股份有限公司 光學活性二環γ-胺基酸衍生物及其製造方法
WO2018166855A1 (en) 2017-03-16 2018-09-20 Basf Se Heterobicyclic substituted dihydroisoxazoles
CN113045410A (zh) * 2021-03-29 2021-06-29 华东理工大学 一种双环降二萜类化合物及其合成基因及制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3641129A (en) 1969-06-17 1972-02-08 Merck & Co Inc Antifibrinolytic compounds
DE2460891C2 (de) 1974-12-21 1982-09-23 Gödecke AG, 1000 Berlin 1-Aminomethyl-1-cycloalkanessigsäuren und deren Ester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
US4087544A (en) * 1974-12-21 1978-05-02 Warner-Lambert Company Treatment of cranial dysfunctions using novel cyclic amino acids
ATE323067T1 (de) 1997-10-27 2006-04-15 Warner Lambert Co Zyklische aminosäuren und deren derivate als arzneimittel

Also Published As

Publication number Publication date
HRP20040709A2 (en) 2004-12-31
SV2001000188A (es) 2001-09-07
BG106719A (bg) 2003-02-28
DOP2000000083A (es) 2002-03-30
YU73004A (sh) 2005-11-28
KR20020040900A (ko) 2002-05-30
UA72931C2 (uk) 2005-05-16
KR100593349B1 (ko) 2006-06-26
OA12070A (en) 2003-11-10
PE20010740A1 (es) 2001-07-27
PL354607A1 (en) 2004-01-26
GT200000183AA (es) 2005-06-17
ATE358116T1 (de) 2007-04-15
DE60019628D1 (de) 2005-05-25
PA8505201A1 (es) 2002-08-29
DE60034157D1 (de) 2007-05-10
US20040152779A1 (en) 2004-08-05
ZA200202543B (en) 2003-09-23
CU23112A3 (es) 2006-02-27
CR6620A (es) 2004-02-02
HUP0203325A2 (hu) 2003-02-28
EE200200211A (et) 2003-06-16
ECSP045393A (es) 2004-10-23
AP2002002517A0 (en) 2002-06-30
HRP20020428A2 (en) 2005-02-28
TW200505824A (en) 2005-02-16
US6689906B1 (en) 2004-02-10
EP1226110B1 (en) 2005-04-20
TR200500221T2 (tr) 2005-03-21
PT1226110E (pt) 2005-07-29
AU778871B2 (en) 2004-12-23
CN1382118A (zh) 2002-11-27
DE60034157T2 (de) 2007-12-13
NZ517961A (en) 2002-12-20
HK1049826A1 (en) 2003-05-30
ES2237464T3 (es) 2005-08-01
JP2005036009A (ja) 2005-02-10
CN1165518C (zh) 2004-09-08
JP3632191B2 (ja) 2005-03-23
BG108860A (en) 2006-03-31
WO2001028978A1 (en) 2001-04-26
EA200200293A1 (ru) 2002-10-31
EP1506955B1 (en) 2007-03-28
ES2282785T3 (es) 2007-10-16
HUP0203325A3 (en) 2003-12-29
CA2386297A1 (en) 2001-04-26
NO20021780D0 (no) 2002-04-16
US6835751B2 (en) 2004-12-28
NO20043663L (no) 2002-04-16
MXPA02003229A (es) 2002-09-30
HK1049826B (zh) 2005-02-25
AU1092001A (en) 2001-04-30
IL149143A0 (en) 2002-11-10
CO5280060A1 (es) 2003-05-30
AP2004003186A0 (en) 2004-12-31
JP3744928B2 (ja) 2006-02-15
KR20060013701A (ko) 2006-02-13
KR100566462B1 (ko) 2006-03-31
BR0014972A (pt) 2002-07-16
MA26842A1 (fr) 2004-12-20
ATE293590T1 (de) 2005-05-15
DE60019628T2 (de) 2006-01-19
BR0014972B1 (pt) 2011-09-06
IL164060A0 (en) 2005-12-18
IS7497A (is) 2004-10-08
IS6348A (is) 2002-04-17
EP1506955A1 (en) 2005-02-16
TWI225855B (en) 2005-01-01
HN2000000224A (es) 2001-04-11
SI1226110T1 (en) 2005-08-31
JP2003512348A (ja) 2003-04-02
AR045456A2 (es) 2005-10-26
MY127678A (en) 2006-12-29
HRP20020428B1 (en) 2006-02-28
CZ295960B6 (cs) 2005-12-14
AR026087A1 (es) 2002-12-26
DZ3197A1 (fr) 2001-04-26
AU2005201268A1 (en) 2005-04-21
IL149143A (en) 2007-02-11
CA2386297C (en) 2010-02-09
YU29302A (sh) 2005-06-10
NO20021780L (no) 2002-04-16
EP1226110A1 (en) 2002-07-31
SK5232002A3 (en) 2003-07-01
EA005206B1 (ru) 2004-12-30
GEP20043297B (en) 2004-01-12
GT200000183A (es) 2000-10-19
CZ20021310A3 (cs) 2003-05-14

Similar Documents

Publication Publication Date Title
TR200500221T2 (tr) Farmasötik Maddeler Olarak Bisiklik Amino Asitler
MY134865A (en) Fused bicyclic or tricyclic amino acids
BR0309875A (pt) métodos e composições para tratamento de distúrbios do sistema nervoso periférico e novos compostos úteis para isto
DE69738581D1 (de) Menschliche dnase i hyperaktive varianten
MXPA02012272A (es) Compuestos heterociclicos que son inhibidores de la enzima dipeptidilpeptidasa-iv.
TW200740801A (en) N-heteroarylpiperazinyl ureas as modulators of fatty acid amide hydrolase
MY140840A (en) Acylated, heteroaryl-condensed cycloalkenylamines and their use as pharmaceuticals
PL374443A1 (en) Novel pyrimidineamide derivatives and the use thereof
NO20053855D0 (no) 1-fenylalkankarboksylsyrederivater til behandling av neurodegenerative sykdommer.
DE60112766D1 (de) Verwendung von derivaten der valproinsäureamide und 2-valproinsäureamid zur behandlung und prävention von schmerzen und/oder kopfschmerzen
DE60126829D1 (de) Kombination von drei Substanzen zur Vorbeugung und Behandlung von Arthritis
IL163951A0 (en) New heterocyclic compounds process for their preparation and pharmaceutical compositions containing them and their use in medicine
CY1109975T1 (el) Παρα-αλκυλ-υποκατεστημενα αμιδια ν-(4-υδροξυ-3-μεθοξυ-βενζυλο) κιναμμωμικου οξεος και η χρησιμοποιηση τους για την παρασκευη φαρμακων
ATE290857T1 (de) Bretyliumhaltige zusammensetzungen und kits und deren verwendung zur vorbeugung und behandlung cardiovaskulärer erkrankungen
ATE225171T1 (de) Aminosäurederivate zur behandlung von schlaganfall
ATE313561T1 (de) Vgf polypeptide und verfahren zur behandlung von vgf-erkrankungen
ID23184A (id) Garam-garam peptida bpc dengan aktivitas organoprotektif proses pembuatan dan penggunaannya dalam terapi
IL153182A0 (en) Heterocyclic compounds, which are inhibitors of the enzyme dpp-iv
ATE418558T1 (de) Darstellung von 1-aza-2-oxadibenzoäe,hüazulenen und deren verwendung bei der herstellung pharmazeutischer formulierungen zur behandlung und prävention von krankheiten und erkrankungen des zentralen nervensystems
ATE382342T1 (de) Pomolsäure zur behandlung von mehrfachresistenten tumoren
TW200512193A (en) Pyridinyl carbamates